

# Chemical Science

Volume 14  
Number 40  
28 October 2023  
Pages 10983–11284

rsc.li/chemical-science



ISSN 2041-6539

Cite this: *Chem. Sci.*, 2023, 14, 11033

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 22nd July 2023  
Accepted 5th September 2023

DOI: 10.1039/d3sc03785a

rsc.li/chemical-science

## Catalytic olefin metathesis in blood†

Igor Nasibullin,<sup>a</sup> Hiromasa Yoshioka,<sup>a</sup> Akari Mukaimine,<sup>a</sup> Akiko Nakamura,<sup>a</sup> Yuriko Kusakari,<sup>a</sup> Tsung-Che Chang<sup>\*a</sup> and Katsunori Tanaka<sup>ab</sup>

The direct synthesis of drugs *in vivo* enables drugs to treat diseases without causing side effects in healthy tissues. Transition-metal reactions have been widely explored for uncaging and synthesizing bioactive drugs in biological environments because of their remarkable reactivity. Nonetheless, it is difficult to develop a promising method to achieve *in vivo* drug synthesis because blood cells and metabolites deactivate transition-metal catalysts. We report that a robust albumin-based artificial metalloenzyme (ArM) with a low loading (1–5 mol%) can promote Ru-based olefin metathesis to synthesize molecular scaffolds and an antitumor drug in blood. The ArM retained its activity after soaking in blood for 24 h and provided the first example of catalytic olefin cross metathesis in blood. Furthermore, the cyclic-Arg-Gly-Asp (cRGD) peptide-functionalized ArM at lower dosages could still efficiently perform *in vivo* drug synthesis to inhibit the growth of implanted tumors in mice. Such a system can potentially construct therapeutic drugs *in vivo* for therapies without side effects.

## Introduction

All therapeutic drugs have side effects,<sup>1</sup> some of which are serious, resulting in permanent damage to the body, or even life-threatening. A straightforward method to solve this problem is to directly synthesize therapeutic drugs at disease sites to avoid unwanted side effects against healthy tissues. If this goal can be achieved, numerous effective drugs known to have harmful side effects can be utilized again for disease treatment, thereby advancing the fields of drug discovery and life sciences. To minimize the burden on the body and maximize therapeutic effects, a method that is biocompatible and exhibits robust catalytic ability to produce the necessary amounts of drugs *in vivo* is desirable.

One strategy for minimizing the adverse effects of drugs is based on the concept of prodrugs, which are inactive derivatives of drugs that undergo an enzymatic and/or chemical transformation to generate the active forms.<sup>2</sup> In the literature, numerous studies have demonstrated the controllable production of drugs in biological systems *via* prodrug activation with natural enzymes or in the disease microenvironment (*e.g.*, acidic pH).<sup>2</sup> Because such enzymes or microenvironments are widely distributed in healthy tissues, this approach has off-target side effects.<sup>3</sup> With advances in bio-orthogonal click-to-

release chemistry over the past several decades, many researchers have shifted their focus to developing prodrug uncaging strategies. With this approach, the relevant functional groups of drugs (*e.g.*, amine, hydroxyl, or acid groups) are masked using abiotic small molecules, which can then be cleaved *via* an external trigger,<sup>4</sup> improving the specificity of drug release. This strategy, however, is not applicable for regulating the bioactivity of drugs that do not contain the aforementioned functional groups.

Various transition-metal catalysts have been widely explored for uncaging prodrugs because they display remarkable catalytic reactivity in myriad chemical transformations. Such transformations include deprotection reactions such as dealylation (Ru, Pd),<sup>5–10</sup> depropargylation (Pd, Au, Pt),<sup>11–14</sup> azide reduction (Fe, Ru),<sup>15,16</sup> pentynoyl amide cleavage (Pt),<sup>13</sup> 2-alkynylbenzamide decaging (Au),<sup>17</sup> and ring-closing metathesis (RCM)-triggered 1,4-elimination (Ru).<sup>18</sup> In addition to uncaging prodrugs, some studies have recently demonstrated the use of transition-metal-catalyzed bond formation reactions to synthesize drugs, including Suzuki–Miyaura coupling (Pd),<sup>19</sup> alkyne hydroamination (Au),<sup>20</sup> azide–alkyne cycloaddition (Cu),<sup>21,22</sup> olefin metathesis (Ru),<sup>23,24</sup> and transfer hydrogenation (Pd).<sup>25</sup> Because of biocompatibility, most of the aforementioned examples of transition-metal-mediated reactions are limited to use in cell culture environments and microorganisms. The examples of reactions that work in live mammals (*in vivo*)<sup>7–9,22,24,25</sup> have been limited because of the highly complex composition in the bloodstream of the body, where hundreds of different serum proteins, complex metabolites (*e.g.*, glutathione (GSH)), and numerous blood cells will quickly deactivate transition-metal catalysts (Fig. 1A). The majority of these *in vivo* examples have involved nanocarriers with encapsulated

<sup>a</sup>Biofunctional Synthetic Chemistry Laboratory, Cluster for Pioneering Research RIKEN, Wako-shi, Saitama, 351-0198, Japan. E-mail: chang.t.ac@m.titech.ac.jp; kotzenori@riken.jp

<sup>b</sup>Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, Meguro-ku, Tokyo, 152-8552, Japan

† Electronic supplementary information (ESI) available: Experimental procedure, compound data, and NMR spectra. See DOI: <https://doi.org/10.1039/d3sc03785a>





**Fig. 1** Catalytic olefin metathesis in blood. (A) A primary requirement for applying transition-metal catalyzed reactions in blood is to protect their activity to avoid rapid deactivation by numerous serum proteins, metabolites, and blood cells. (B) A Ru–Cl ruthenium complex encapsulated by human serum albumin to form a biocompatible artificial metalloenzyme (ArM) (**AlBRu–Cl**). (C) The albumin-based Ru–I-containing ArM (**AlBRu–I**) can catalyze ring-closing metathesis (RCM), sequential RCM/aromatization, and olefin cross metathesis (CM) reactions in blood.

transition metals because the large surface-area-per-volume ratio of nanocarriers enables the loading of greater amounts of metal catalysts and thereby enhances the reaction rates. However, they have been used in excess rather than in catalytic quantities to produce the required amounts of desired products *in vivo*, indicating that the blood environment substantially hindered the reactivity of metallic nanocarriers. Notably, Völker and Meggers have developed a Ru complex that can catalyze the deallylation of a substrate in blood serum.<sup>5</sup> Although 10 mol% of the Ru complex could afford the product in 30% yield, blood serum is much less complex than blood because it does not contain any white/red blood cells or platelets. A method that implements highly efficient catalytic organometallic reactions in blood has not yet been reported.

Artificial metalloenzymes (ArMs) are the result of inserting transition-metal complexes into protein scaffolds of interest, which can impart enhanced biofunctionality to the anchored metal catalysts and facilitate non-natural reactions under mild conditions.<sup>26</sup> Previously, our group has developed a biocompatible ArM<sup>23</sup> in which a Hoveyda–Grubbs complex, Ru–Cl, is anchored into a hydrophobic binding pocket of human serum

albumin (HSA) (**AlBRu–Cl**) through the interaction of a coumarin moiety with the cavity (Fig. 1B). The negatively charged surface of HSA prevented the charged GSH from entering the metal-binding site, enabling the bound Ru catalyst to be protected even in the presence of GSH at concentrations as high as 20 mM in phosphate buffered saline (PBS) solution. Moreover, we recently reported that a cancer-targeting glycosylated **AlBRu–Cl** could mediate Ru-based olefin metathesis for synthesis of a drug in mice to induce tumor growth inhibition; however, a high dose of the glycosylated **AlBRu–Cl** (116 mg kg<sup>−1</sup>) was required.<sup>24</sup> This indicates that the catalytic reactivity of the ArM *in vivo* should be improved. Building upon these results, we propose an albumin-based Ru–I-containing ArM (**AlBRu–I**) that can efficiently manipulate olefin metathesis in blood (Fig. 1C). We found that just 1–5 mol% of **AlBRu–I** can catalyze various substrates in blood in substantial yields, including RCM, sequential RCM/aromatization, and the first example of olefin cross-metathesis reactions. Importantly, after being soaked in blood for 24 h, **AlBRu–I** still exhibited outstanding catalytic reactivity, highlighting its robust stability in blood. In particular, the cyclic-Arg-Gly-Asp (cRGD) peptide-functionalized **AlBRu–I** at lower dosages (20 and 40 mg kg<sup>−1</sup>) could efficiently perform *in vivo* drug synthesis to inhibit the growth of implanted tumors in mice, highlighting the significant potential of the ArM for future therapeutic applications.

## Results and discussion

### Catalytic activity investigation of a Ru–I-based ArM (**AlBRu–I**) in blood

Olefin metathesis is one of the most efficient methods for building new carbon–carbon double bonds. Davis and coworkers reported the first example of the modification of proteins in an aqueous buffer solution using olefin cross metathesis by the Hoveyda–Grubbs second-generation catalyst.<sup>27</sup> Ward and coworkers conducted groundbreaking research on in-cell RCM by assembling a Ru-based ArM in *Escherichia coli*,<sup>28</sup> while Schunck and Mecking very recently used a Ru catalyst to perform cross metathesis of unsaturated fatty acids in microalgae.<sup>29</sup> Although Ru-based olefin metathesis has been applied to live microbes, these examples were strictly carried out in a thiol-free area to avoid deactivation of the Ru by GSH such as the periplasm of *E. coli* or the lipid vesicles of microalgae. We previously found that **AlBRu–Cl** can catalytically convert substrates *via* RCM in the presence of GSH in PBS solution. Although **AlBRu–Cl** was able to convert a prodrug *via* sequential RCM/aromatization in a blood mixture of blood/PBS/1,4-dioxane (5:4:1), a high loading of it (10 mol%) was required to achieve a good conversion yield (46%).<sup>24</sup> The capacity of **AlBRu–Cl** to catalyze other types of olefin metathesis for various substrates in blood solution has not yet been investigated. First, we examined the capacity of **AlBRu–Cl** with a low loading (1 mol%) to catalyze RCM for model substrate **1** in the same blood mixture solution (Fig. 2A). However, the conversion yield of **2** was unsatisfactory (11%, entry 1). To improve the RCM reactivity of **AlBRu–Cl** in blood, we tested longer reaction times (entry 2) or a greater loading amount of





**Fig. 2** Catalytic activity investigation of Ru-based ArMs for ring-closing metathesis in blood. (A) Reactivity studies of substrate **1** (2 mM) with **AlbRu-Cl**–**I** (1 or 2.5 mol%) and **AquaMet** catalyst (1 mol%) in a mixture of blood/PBS/1,4-dioxane (5 : 4 : 1) (\*\*8 : 1 : 1). (B) To determine the time and extent of Ru protection, a series of experiments were run as illustrated. The indicated Ru catalysts (1 mol%) were preincubated in blood for a specific time (0, 5, 15, 30, and 60 min for **Ru-I/Cl**; 0, 5, 15, 45, 120, and 360 min for **AlbRu-Cl**; and 0, 5, 15, 45, 120, and 360 min, and 24 h for **AlbRu-I**), followed by reaction initiation using **1** (2 mM). After a reaction time of 3 h, the yield of **2** was measured. (C) Graphical representation of stability results of the Ru catalysts in blood. (D) Substrate scope for testing ring-closing olefin and enyne metathesis. Given HPLC yields were determined by HPLC analysis (peak retention times relative to product standards, followed by MS analysis for confirmation, and calculation of resultant yields based on product standard curves). Error bars represent the s.d. of three independent measurements. The blood used here was commercially available sheep blood. Abbreviations: Ts, 4-toluenesulfonyl; N/R, no reaction.

**AlbRu-Cl** (entry 3); however, neither test showed a substantial increase in the RCM yield in blood.

We drew inspiration from the results of Skowerski and coworkers<sup>30</sup>—specifically, their finding that steric hindrance in the proximity of the Ru center as a result of bulky iodides can stabilize the active intermediates—and prepared another Ru-based ArM (**AlbRu-I**) with Ru-I as an anchored metal catalyst. Surprisingly, **AlbRu-I** exhibited dramatically improved catalytic activity for RCM, affording the desired **2** in good yield (58%, entry 4) compared with the yield achieved with **AlbRu-Cl** (11%, entry 1). As expected, increasing the amount of **AlbRu-I** to 2.5 mol% resulted in an excellent conversion yield of **2** (88%, entry 5). In addition, the catalytic RCM for substrate **1** was tested in a mixture that contained 80% blood, and **AlbRu-I** still showed high activity (entry 6). A highly water-soluble Ru complex, **AquaMet** catalyst,<sup>31</sup> has been shown to effectively catalyze RCM in aqueous media. However, as expected by the report of Schwaneberg,<sup>32</sup> the reactivity of the **AquaMet** catalyst in the blood mixture was completely abolished (entry 7). The results in Fig. 2A clearly demonstrate the robust catalytic activity of **AlbRu-I** because even using a tiny amount of ArMs was found to achieve RCM in excellent yields in blood.

In the next experiment, we focused on the approximate duration of the stability of Ru-based ArMs (**AlbRu-I-Cl**) in blood. As depicted in Fig. 2B, a series of experiments were carried out in which the **AlbRu-I-Cl** and free-in-solution catalysts (**Ru-I-Cl**) as controls were preincubated in blood for a specific time. Substrate **1** was then added to the mixture, and the yield of **2** was measured after a 3 h reaction. As expected, the **Ru-I-Cl** catalysts were deactivated after a few minutes of preincubation in the blood mixture (green and gray lines, Fig. 2C). By contrast, both **AlbRu-I-Cl** still gave substantial yields of **2** even after 6 h of preincubation (blue and red lines, Fig. 2C). Importantly, although **AlbRu-I** was used in a very small amount (1 mol%), it still produced a high yield of **2** (21%) after 24 h of preincubation in the blood mixture, demonstrating its exceptional biocompatibility and excellent catalytic activity for RCM. In comparison with other known ArMs and metallic nanocarriers, **AlbRu-I** is the first to demonstrate that it can carry out a highly efficient catalytic organometallic reaction in such a challenging biological environment.

The **AlbRu-I-Cl** catalysts were further investigated with a small substrate scope to confirm the remarkable reactivity of **AlbRu-I** in blood. Under the standard conditions



corresponding to Fig. 2D, 2.5 mol% of ArMs and 2 mM of substrates were used in the mixture of blood/PBS/1,4-dioxane (5 : 4 : 1). This result clearly demonstrates that, compared with **AlbRu-Cl**, **AlbRu-I** showed a substantially greater activity toward the RCM over substrates 3–7, resulting in substantial yields (21–60%). Notably, **AlbRu-I** could also catalyze ring-closing enyne metathesis of **8** in excellent yield (79%). The overall results in Fig. 2 clearly show that **AlbRu-I** is a capable catalyst for promoting olefin metathesis in blood.

### Substrate scope for the **AlbRu-I** in blood

Encouraged by these promising results, we shifted to investigating the applicability of **AlbRu-I** with various substrates in blood (Fig. 3). These substrates were divided into three groups for testing: (1) RCM; (2) sequential RCM/aromatization; and (3) olefin cross metathesis. **AlbRu-I** catalyzed RCM for substrates **11–17** in good yields (15–64%) (Fig. 3A), whereas substrates **9** and **10** gave relatively low yields (7–8%). These results can be explained by the products with five- or six-membered rings being more stable. Substrate **18** resulted in the lowest yield, likely because of its structural effect. Collectively, the results in Fig. 2D and 3A show that **AlbRu-I** exhibits strong potential to be used in the synthesis of carbocyclic molecules in blood for various applications.

Previous studies conducted by Ward and coworkers have demonstrated that, in RCM reactions of 1,4,7-trien-3-ols through Ru-based ArMs, spontaneous aromatization can proceed *via* 1,4-elimination to produce phenyl moieties.<sup>18,33,34</sup> Investigating sequential RCM/aromatization reactions in blood is especially important because many bioactive drugs contain at least one phenyl moiety in their structure. Heterocyclic precursors **19–24** were prepared for the RCM/aromatization (Fig. 3B). Even though **AlbRu-I** did not work with substrates **19** and **20**, the carbazole **21**, biphenyl **22**, tetrahydroisoquinoline **23**, and indole **24** precursors gave substantial yields in the blood mixture (3–28%). In particular, a 28% yield of the indole product from **24** was obtained, which is highly promising for drug design because myriad bioactive compounds contain an indole moiety. We previously reported that the allylic hydroxyl groups of **31** protected with a pivalate group could facilitate 1,4-elimination in the RCM/aromatization process to afford naphthalene in aqueous solution.<sup>24</sup> Therefore, in the present work, we tested a set of substituted naphthalene precursors **25–31** (Fig. 3B). As a result, **AlbRu-I** catalyzed the RCM/aromatization for substrates **25–30** to generate the different substituted naphthalenes in good yields (12–28%). In particular, substrate **31** produced naphthalene in blood in an excellent yield (59%). The results in Fig. 3B offer a useful technique for producing various heterocyclic and naphthalene-related chemicals in blood. Although the aforementioned reaction yields were not high, we note that these Ru-based reactions were carried out in blood, not in an organic solvent or aqueous buffer solution.

The reactivity of olefin cross metathesis in blood warrants investigation because it can facilitate the creation of complex molecules by linking two alkene fragments. After a detailed investigation of the cross-metathesis conditions (see Fig. S83†), larger amounts of **AlbRu-I** (5 mol%) and substrates **32–37** (10–

20 mM) were used to afford higher product yields (Fig. 3C). Initially, olefin homodimerization of **32–34** catalyzed by **AlbRu-I** was tested in blood before olefin cross metathesis was investigated. Although dimerization of **32** gave a lower yield (7%), the exciting outcome in blood encouraged us to investigate further (Fig. 3C-I). Under the sulfur-assisted olefin metathesis mechanism reported by Davis and coworkers,<sup>27</sup> the homodimerization yields of **33** and **34** were increased dramatically, with the 31% yield of **34** being particularly noteworthy. Importantly, **AlbRu-I** successfully mediated the cross metathesis of **34** with either **33**, **35**, **36**, or **37** in blood (Fig. 3C-II). Although **35–37** gave lower yields of products (1–3%) because of their lower reactivity, these examples show the first demonstration of the feasibility of carrying out olefin cross metathesis in blood. Moreover, another substrate containing a sulfur moiety, **33**, achieved a substantial yield (17%), clearly demonstrating the first example of implementing catalytic olefin cross metathesis in blood. The results in Fig. 3C represent a new avenue for constructing complex molecules in blood *via* olefin cross metathesis.

### *In vivo* drug synthesis against tumour growth

As mentioned in the introduction, the direct synthesis of bioactive drugs *in vivo* is an important vision for future drug discovery and other biomedical applications. For localized *in vivo* drug synthesis to avoid off-target effects, a suitable targeting system was needed to direct the biocatalysts to specific disease sites within the body. As shown in Fig. 4A, a cyclic-Arg-Gly-Asp (cRGD) pentapeptide is frequently used as a drug delivery system through an interaction with the overexpression of integrin in cancer cells.<sup>35</sup> Recently, we revealed that after injection into mice, the cRGD-conjugated human serum albumin (cRGD)HSA could rapidly and specifically accumulate into tumors derived from SW620 colon cancer cells after just 4 hours.<sup>36</sup> For the following cancer-targeting studies, the cRGD-linked ArMs bound with Ru-Cl/I ((cRGD)**AlbRu-Cl** and (cRGD)**AlbRu-I**) were used as the biocatalysts for localized *in vivo* drug synthesis (Fig. 4A). In the literature, combretastatin-A4 (CA-4) and its derivatives containing drug **39** showed a high-affinity tubulin ligand with anticancer characteristics and inhibited tumor growth *in vivo* through anti-angiogenic mechanisms<sup>37</sup> (Fig. 4B). As mentioned earlier in the introduction, we have reported that a cancer-targeting glycosylated **AlbRu-Cl** can mediate RCM/aromatization for synthesizing **39** from the prodrug **38** in mice to induce tumor growth inhibition;<sup>24</sup> however, a high dose of the glycosylated **AlbRu-Cl** (116 mg kg<sup>−1</sup>) was necessary. To improve the efficiency of *in vivo* drug synthesis, the last stage of this study was to investigate using lower dosages of (cRGD)**AlbRu-I** to produce **39** from **38** to treat subcutaneous SW620-xenografted mice (Fig. 4C).

Before moving on to animal experiments, the *in vitro* data in Fig. 4B showed that, compared with (cRGD)**AlbRu-Cl**, (cRGD)**AlbRu-I** again demonstrated excellent catalytic activity in blood because 2.5 mol% of it could produce drug **39** in substantial yield (40%), indicating great potential for producing a high concentration of **39** from **38** even if a lower dosage of (cRGD)**AlbRu-I** is used *in vivo*. Likewise, based on the results of cell-based





**Fig. 3** Substrate scope for **AlbRu-I** in blood. (A) Ring-closing metathesis (RCM). (B) Sequential RCM/aromatization. (C) Olefin cross-metathesis. Reaction conditions: substrates (2 mM for (A) and (B) and 10 mM for (C)) and **AlbRu-I** (2.5 mol% for (A) and (B) and 5.0 mol% for (C)) were used in a mixture of blood/PBS/1,4-dioxane (5 : 4 : 1). Incubations were carried out in triplicate at 37 °C for 3 h. Given HPLC yields were determined by HPLC analysis (peak retention times relative to product standards, followed by MS analysis for confirmation, and calculation of resultant yields based on product standard curves). Abbreviations: Piv, pivaloyl; Ts, 4-toluenesulfonyl; N/R, no reaction.

experiments (see Fig. S88 and S89<sup>†</sup>), it was clearly demonstrated that (**cRGD**)**AlbRu-I** with a low concentration (0.5 μM) could still effectively perform drug **39** synthesis to induce a significant suppression in SW620 cancer cell growth, whereas (**cRGD**)**AlbRu-Cl** failed to convert **38** under the same setting conditions.

With these promising *in vitro* results, as shown in Fig. 4D, six groups of mice were arranged to receive the indicated compounds [saline, **39** only, co-treatment with (**cRGD**)**AlbRu-Cl** (20 or 40 mg kg<sup>-1</sup>) and **38**, or co-treatment with (**cRGD**)**AlbRu-I**

(20 or 40 mg kg<sup>-1</sup>) and **38**] *via* intravenous administration every day for 8 consecutive days. As a control group, a saline solution was used to replace compounds in the treatment protocol. With the treatment groups, (**cRGD**)**AlbRu** was first administered, followed by prodrug **38**. As a result, co-treatment with (**cRGD**)**AlbRu-Cl** (20 or 40 mg kg<sup>-1</sup>) and **38** (Fig. 4D, gray and green lines, respectively) showed the same rate of tumor growth as the saline group (Fig. 4D, black line). This illustrated that the *in vivo* reactivity of (**cRGD**)**AlbRu-Cl** at these dosages was insufficient





**Fig. 4** *In vivo* drug synthesis against SW620 tumor growth in mice. (A) Schematic illustration of cancer-targeting (cRGD)AlbRu. (B) Investigation of the catalytic reactivity of RCM/aromatization by (cRGD)AlbRu (2.5 mol%) in a mixture of blood/PBS/1,4-dioxane (5 : 4 : 1) for transformation of prodrug **38** (2 mM) into drug **39**. Given HPLC yields were determined by HPLC analysis (peak retention times relative to product standards, followed by MS analysis for confirmation, and calculation of resultant yields based on product standard curves). Error bars represent the s.d. of three independent measurements. (C) To highlight the biocatalytic reactivity of the (cRGD)AlbRu-I, the objective was to apply *in vivo* drug synthesis via intravenous administration to treat subcutaneous SW620-xenografted mice. Tumors were initially implanted in mice and developed over 1 day before therapy. Dosages were applied in daily injections spread out over 8 days. (D) Effects of tumor therapy on tumor volume changes of xenograft mice subjected to the following treatments: saline (black), drug **39** (32.5 mg kg<sup>-1</sup>, orange), prodrug **38** (58 mg kg<sup>-1</sup>) + (cRGD)AlbRu-Cl (20 or 40 mg kg<sup>-1</sup>, gray or green, respectively), and prodrug **38** (58 mg kg<sup>-1</sup>) + (cRGD)AlbRu-I (20 or 40 mg kg<sup>-1</sup>, red or blue, respectively). Data in (D) are represented as mean value ± SD, *n* = 3 biologically independent samples.

to synthesize the required amount of drug, resulting in failure in tumor inhibition. In contrast, co-treatment with (cRGD)AlbRu-I (20 or 40 mg kg<sup>-1</sup>) and **38** (Fig. 4D, red and blue lines, respectively) resulted in a dose-dependent depreciation in the rate of tumor growth compared to the saline group. These results demonstrated that, compared with (cRGD)AlbRu-Cl, (cRGD)AlbRu-I at lower dosages was still able to exhibit robust catalytic reactivity to mediate RCM/aromatization for progressing *in vivo* synthesis of **39** for cancer treatment. Moreover, a notable finding was that combining (cRGD)AlbRu-I (20 or 40 mg kg<sup>-1</sup>) with **38** resulted in a stronger suppression of tumor growth than treatment with drug **39** alone (Fig. 4D, orange line). This would suggest that cancer targeting is also critical for the cancer treatment by co-treatment of (cRGD)AlbRu-I with **38** because localized drug synthesis can be achieved to generate high concentrations of drug in specific disease sites, leading to the enhancement of therapy effects.

## Conclusions

This study significantly advances the research fields of Ru-based olefin metathesis under biological conditions and ArMs. Overall, just 1–5 mol% AlbRu-I could catalyze three types of olefin metathesis reactions in blood to construct carbocyclic, heterocyclic, phenyl rings, and olefin dimerization in substantial yields. AlbRu-I also showed robust stability for 24 h in blood, expanding the biocompatibility of ArMs and opening the door

for the development of general metal-based ArMs for catalytic reactions in blood. Moreover, the cancer-targeting AlbRu-I at a low dosage was able to elicit significant tumor growth inhibition in mice through localized synthesis of an antitumor drug, highlighting the significant potential of the ArM for future therapeutic applications. Since applications of click-to-release chemistry are limited to drug release, this promising metallic system offers a new avenue for building bioactive drugs and functional molecules *in vivo*, enabling the development of innovative drug therapies without side effects.

## Data availability

The datasets supporting this article have been uploaded as part of the ESI.†

## Author contributions

Conceptualization: I. N. and K. T.; methodology: I. N., T.-C. C., and K. T.; investigation: I. N., T.-C. C., H. Y., A. M., A. N. and Y. K.; visualization: T.-C. C., I. N., and K. T.; funding acquisition: K. T.; project administration: K. T.; supervision: K. T.; writing – original draft: T.-C. C. and K. T.

## Conflicts of interest

There are no conflicts to declare.



## Acknowledgements

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of RIKEN and approved by the Animal Ethics Committee of RIKEN (W2019-2-049). This work was financially supported by the AMED Grant JP15KM0908001 (K. T.), a research grant from the Astellas Foundation (K. T.), Mizutani Foundation for Glycoscience (K. T.), and JSPS KAKENHI Grant Numbers JP21H02065 (K. T.) and JP21K19042 (K. T.). HRMS (EI), and DQF-COSY were acquired by the Molecular Structure Characterization Unit (RIKEN CSRS, Wako).

## Notes and references

- O. Osanlou, M. Pirmohamed and A. K. Daly, *Adv. Pharmacol.*, 2018, **83**, 155.
- V. Abet, F. Filace, J. Recio, J. Alvarez-Builla and C. Burgos, *Eur. J. Med. Chem.*, 2017, **127**, 810.
- K. M. Huttunen, H. Raunio and J. Rautio, *Pharmacol. Rev.*, 2011, **63**, 750.
- X. Ji, Z. Pan, B. Yu, L. K. De La Cruz, Y. Zheng, B. Ke and B. Wang, *Chem. Soc. Rev.*, 2019, **48**, 1077.
- T. Völker and E. Meggers, *ChemBioChem*, 2017, **18**, 1083.
- M. I. Sánchez, C. Penas, M. E. Vázquez and J. L. Mascareñas, *Chem. Sci.*, 2014, **5**, 1901.
- M. A. Miller, B. Askevold, H. Mikula, R. H. Kohler, D. Pirovich and R. Weissleder, *Nat. Commun.*, 2017, **8**, 15906.
- T. L. Bray, M. Salji, A. Brombin, A. M. Pérez-López, B. Rubio-Ruiz, L. C. A. Galbraith, E. E. Patton, H. Y. Leung and A. Unciti-Broceta, *Chem. Sci.*, 2018, **9**, 7354.
- M. A. Miller, H. Mikula, G. Luthria, R. Li, S. Kronister, M. Prytskach, R. H. Kohler, T. Mitchison and R. Weissleder, *ACS Nano*, 2018, **12**, 12814.
- Y. Okamoto, R. Kojima, F. Schwizer, E. Bartolami, T. Heinisch, S. Matile, M. Fussenegger and T. R. Ward, *Nat. Commun.*, 2018, **9**, 1943.
- J. T. Weiss, J. C. Dawson, K. G. Macleod, W. Rybski, C. Fraser, C. Torres-Sánchez, E. E. Patton, M. Bradley, N. O. Carragher and A. Unciti-Broceta, *Nat. Commun.*, 2014, **5**, 3277.
- A. M. Pérez-López, B. Rubio-Ruiz, V. Sebastián, L. Hamilton, C. Adam, T. L. Bray, S. Irusta, P. M. Brennan, G. C. Lloyd-Jones, D. Sieger, J. Santamaría and A. Unciti-Broceta, *Angew. Chem., Int. Ed.*, 2017, **56**, 12548.
- B. L. Oliveira, B. J. Stenton, V. B. Unnikrishnan, C. R. de Almeida, J. Conde, M. Negrão, F. S. S. Schneider, C. Cordeiro, M. G. Ferreira, G. F. Caramori, J. B. Domingos, R. Fior and G. J. L. Bernardes, *J. Am. Chem. Soc.*, 2020, **142**, 10869.
- M. Sancho-Albero, B. Rubio-Ruiz, A. M. Pérez-López, V. Sebastián, P. Martín-Duque, M. Arruebo, J. Santamaría and A. Unciti-Broceta, *Nat. Catal.*, 2019, **2**, 864.
- R. Huang, C.-H. Li, R. Cao-Milán, L. D. He, J. M. Makabenta, X. Zhang, E. Yu and V. M. Rotello, *J. Am. Chem. Soc.*, 2020, **142**, 10723.
- J. Chen, K. Li, J. S. L. Shon and S. C. Zimmerman, *J. Am. Chem. Soc.*, 2019, **142**, 4565.
- K. Vong, T. Yamamoto, T.-C. Chang and K. Tanaka, *Chem. Sci.*, 2020, **11**, 10928.
- V. Sabatino, J. G. Rebelein and T. R. Ward, *J. Am. Chem. Soc.*, 2019, **141**, 17048.
- E. Indrigo, J. Clavadetscher, S. V. Chankeshwara, A. Lilienkampf and M. Bradley, *Chem. Commun.*, 2016, **52**, 14212.
- T.-C. Chang, K. Vong, T. Yamamoto and K. Tanaka, *Angew. Chem., Int. Ed.*, 2021, **60**, 12446.
- S. Li, L. Wang, F. Yu, Z. Zhu, D. Shobaki, H. Chen, M. Wang, J. Wang, G. Qin, U. J. Erasquin, L. Ren, Y. Wang and C. Cai, *Chem. Sci.*, 2017, **8**, 2107.
- F. Wang, Y. Zhang, Z. Liu, Z. Du, L. Zhang, J. Ren and X. Qu, *Angew. Chem., Int. Ed.*, 2019, **58**, 6987.
- S. Eda, I. Nasibullin, K. Vong, N. Kudo, M. Yoshida, A. Kurbangalieva and K. Tanaka, *Nat. Catal.*, 2019, **2**, 780.
- I. Nasibullin, I. Smirnov, P. Ahmadi, K. Vong, A. Kurbangaleva and K. Tanaka, *Nat. Commun.*, 2022, **13**, 39.
- Z. Du, C. Liu, H. Song, P. Scott, Z. Liu, J. Ren and X. Qu, *Chem*, 2020, **6**, 2060.
- H. J. Davis and T. R. Ward, *ACS Cent. Sci.*, 2019, **5**, 1120.
- Y. A. Lin, J. M. Chalker and B. G. Davis, *J. Am. Chem. Soc.*, 2010, **132**, 16805.
- M. Jeschek, R. Reuter, T. Heinisch, C. Trindler, J. Klehr, S. Panke and T. R. Ward, *Nature*, 2016, **537**, 661.
- N. S. Schunck and S. Mecking, *Angew. Chem., Int. Ed.*, 2022, **61**, e202211285.
- A. Tracz, M. Matczak, K. Urbaniak and K. Skowerski, *Beilstein J. Org. Chem.*, 2015, **11**, 1823.
- T. K. Olszewski, M. Bieniek and K. Skowerski, *Org. Process Res. Dev.*, 2020, **24**, 125.
- A. R. Grimm, D. F. Sauer, M. D. Davari, L. Zhu, M. Bocola, S. Kato, A. Onoda, T. Hayashi, J. Okuda and U. Schwaneberg, *ACS Catal.*, 2018, **8**, 3358.
- A. Samanta, V. Sabatino, T. R. Ward and A. Walther, *Nat. Nanotechnol.*, 2020, **15**, 914.
- S. Fischer, T. R. Ward and A. D. Liang, *ACS Catal.*, 2021, **11**, 6343.
- Y. Cheng and Y. Ji, *Eur. J. Pharm. Sci.*, 2019, **128**, 8.
- P. Ahmadi, K. Muguruma, T.-C. Chang, S. Tamura, K. Tsubokura, Y. Egawa, T. Suzuki, N. Dohmae, Y. Nako and K. Tanaka, *Chem. Sci.*, 2021, **12**, 12266.
- M. Su, J. Huang, S. Liu, Y. Xiao, X. Qin, J. Liu, C. Pi, T. Luo, J. Li, X. Chen and Z. Luo, *Sci. Rep.*, 2016, **6**, 28139.

